# UGT3A2

## Overview
UGT3A2 is a gene that encodes the protein UDP glycosyltransferase family 3 member A2, which is part of the UDP glycosyltransferase family. This family of enzymes is involved in the glycosylation of small lipophilic molecules, a process crucial for the detoxification and solubility of hydrophobic compounds. UGT3A2 is distinct in its utilization of UDP-glucose and UDP-xylose as sugar donors, unlike other UGT enzymes that primarily use UDP-glucuronic acid. The protein is expressed in specific tissues such as the thymus, testis, and kidney, and plays a significant role in the metabolism of polycyclic aromatic hydrocarbons (PAHs), converting these environmental carcinogens into more water-soluble forms for excretion. The gene's mutations have been implicated in various cancers, affecting drug metabolism and potentially serving as biomarkers for personalized cancer therapy (MacKenzie2010The; Hu2022The; Vergara2020Altered).

## Structure
UGT3A2 is a member of the UDP glycosyltransferase family, characterized by specific structural features. The primary structure of UGT3A2 includes a signal peptide, a transmembrane domain, and a conserved 44-amino acid signature sequence in the COOH-terminal region, which is crucial for UDP-sugar binding (MacKenzie2010The; Meech2019The). The protein is composed of 523 amino acids, with a homology model including 442 of these residues, indicating that the N- and C-termini were not effectively modeled (Vergara2020Altered).

The secondary structure likely includes alpha-helices and beta-sheets, as suggested by the homology model's similarity to the UGT76G1 template, with a root-mean-square deviation of α-carbon positions of 0.204 Å² (Vergara2020Altered). The tertiary structure involves the folding of these elements into a three-dimensional shape, forming a globular protein. The model shows high similarity to the UGT76G1 template, indicating a conserved fold typical of UGT enzymes (Vergara2020Altered).

UGT3A2 does not have a quaternary structure involving multiple subunits, as no information on oligomerization is provided. The protein also has splice variants, such as UGT3A2del-exon2, which lacks exon 2 and has a molecular mass of approximately 49 kDa (MacKenzie2010The).

## Function
UGT3A2 is a member of the UDP glycosyltransferase family, which plays a crucial role in the glycosylation of small lipophilic molecules. This enzyme catalyzes the transfer of glycosyl groups to substrates, a process important for the detoxification and solubility of hydrophobic compounds, including polycyclic aromatic hydrocarbons (PAHs) (Vergara2020Altered). UGT3A2 utilizes UDP-glucose and UDP-xylose as sugar donors, distinguishing it from other UGT enzymes that primarily use UDP-glucuronic acid (MacKenzie2010The; Meech2019The).

The enzyme is expressed in specific tissues such as the thymus, testis, and kidney, with minimal expression in the liver and gastrointestinal tract, suggesting a specialized role in protecting these organs from toxic insults (MacKenzie2010The). UGT3A2's activity is particularly significant in the metabolism of PAHs, where it facilitates the conversion of these environmental carcinogens into more water-soluble forms, aiding in their excretion from the body (Vergara2020Altered).

In cellular biology, UGT3A2's glycosylation activity is essential for modifying the solubility and stability of various compounds, impacting their biological activity and excretion. This function is vital for maintaining cellular homeostasis and protecting cells from potentially harmful substances (MacKenzie2010The).

## Clinical Significance
Mutations in the UGT3A2 gene have been identified in various human cancers, with significant implications for cancer progression and treatment outcomes. In particular, somatic mutations in UGT3A2 can lead to amino acid substitutions, premature stop codons, and frame-shift truncated proteins, potentially impacting protein function and drug metabolism (Hu2022The). Approximately 45% of the missense mutations in UGT3A2 are considered deleterious, suggesting a substantial effect on protein activity (Hu2022The).

The expression of UGT3A2 is notably variable across different cancer types. It is highly expressed in uterine and testicular cancers but shows low or no expression in other cancer types (Hu2021The). This differential expression pattern may influence the metabolism of anticancer drugs and endogenous molecules, affecting therapeutic efficacy and toxicity (Hu2022The).

Mutations in UGT3A2, particularly those affecting splice sites and untranslated regions, may disrupt normal gene expression and miRNA regulation, potentially altering cancer cell behavior and drug response (Hu2022The). These mutations could serve as biomarkers for predicting clinical outcomes and guiding personalized cancer therapy (Hu2022The). However, the specific clinical significance of UGT3A2 mutations remains to be fully elucidated, necessitating further research.


## References


[1. (Vergara2020Altered) Ana G. Vergara, Christy J. W. Watson, Jeffrey M. Watson, Gang Chen, and Philip Lazarus. Altered metabolism of polycyclic aromatic hydrocarbons by udp-glycosyltransferase 3a2 missense variants. Chemical Research in Toxicology, 33(11):2854–2862, September 2020. URL: http://dx.doi.org/10.1021/acs.chemrestox.0c00233, doi:10.1021/acs.chemrestox.0c00233. This article has 3 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1021/acs.chemrestox.0c00233)

[2. (MacKenzie2010The) Peter I. MacKenzie, Anne Rogers, David J. Elliot, Nuy Chau, Julie-Ann Hulin, John O. Miners, and Robyn Meech. The novel udp glycosyltransferase 3a2: cloning, catalytic properties, and tissue distribution. Molecular Pharmacology, 79(3):472–478, November 2010. URL: http://dx.doi.org/10.1124/mol.110.069336, doi:10.1124/mol.110.069336. This article has 66 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/mol.110.069336)

[3. (Hu2021The) Dong Gui Hu, Shashikanth Marri, Peter I. Mackenzie, Julie-Ann Hulin, Ross A. McKinnon, and Robyn Meech. The expression profiles and deregulation of udp-glycosyltransferase (ugt) genes in human cancers and their association with clinical outcomes. Cancers, 13(17):4491, September 2021. URL: http://dx.doi.org/10.3390/cancers13174491, doi:10.3390/cancers13174491. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13174491)

[4. (Hu2022The) Dong Gui Hu, Shashikanth Marri, Julie-Ann Hulin, Ross A. McKinnon, Peter I. Mackenzie, and Robyn Meech. The somatic mutation landscape of udp-glycosyltransferase (ugt) genes in human cancers. Cancers, 14(22):5708, November 2022. URL: http://dx.doi.org/10.3390/cancers14225708, doi:10.3390/cancers14225708. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14225708)

[5. (Meech2019The) Robyn Meech, Dong Gui Hu, Ross A. McKinnon, Siti Nurul Mubarokah, Alex Z. Haines, Pramod C. Nair, Andrew Rowland, and Peter I. Mackenzie. The udp-glycosyltransferase (ugt) superfamily: new members, new functions, and novel paradigms. Physiological Reviews, 99(2):1153–1222, April 2019. URL: http://dx.doi.org/10.1152/physrev.00058.2017, doi:10.1152/physrev.00058.2017. This article has 272 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1152/physrev.00058.2017)